MaaT Pharma Unveils the First GMP-Compliant European Fecal Microbiota Transfer Platform. Major treatments such as high-dose antibiotic therapies and chemotherapies can lead to serious complications and create a gut microbiota imbalance (formerly called intestinal flora). Thanks to the €16M funding round led by multiple venture capitalists, in the last 18 months, MaaT Pharma aims to correct this imbalance. This biotech company, a specialist in intestinal microbiota, has launched its clinical trials and officially opened its platform for the production of clinical batches on November 3rd, 2016  Read more

MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study.  MaaT Pharma ODYSSEE Study focuses in prevention of dysbiosis complications with autologous fecal microbiota transplantation in Acute Myeloid Leukemia patients undergoing intensive treatment. Read more

Hervé Affagard, CEO and Co-Founder of MaaT Pharma has been awarded the Prize of Health Entrepreneur 2016  by France Biotech.  Read more (French only)